Medicine and Dentistry
Prostate Cancer
100%
Patient
62%
Castration Resistant Prostate Cancer
45%
Man
41%
Therapeutic Procedure
33%
Combination Therapy
26%
Androgen Receptor
22%
Inpatient
20%
Enzalutamide
16%
Prostate Specific Antigen
16%
Metastatic Carcinoma
15%
Overall Survival
14%
Disease
13%
Progression Free Survival
12%
Neoplasm
12%
Analysis
11%
Androgen
10%
Abiraterone
10%
Androgen Deprivation Therapy
10%
Androgen Therapy
9%
Radiation Therapy
9%
DNA Repair
9%
Hormone
8%
Biological Marker
7%
Development
7%
Immunotherapy
7%
Prostatectomy
7%
Docetaxel
7%
PARP Inhibitor
7%
Association
6%
Circulating Tumor Cell
6%
Chemotherapy
6%
Clinical Trial
6%
Prostate Specific Membrane Antigen
6%
Gene
6%
Arm
5%
Hazard Ratio
5%
BRCA2
5%
Gene Mutation
5%
Malignant Neoplasm
5%
Systemic Therapy
5%
Gleason Score
5%
Sipuleucel T
5%
Fluorine-18
5%
DNA Mismatch Repair
5%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
66%
Castration Resistant Prostate Cancer
59%
Androgen
24%
Enzalutamide
23%
Androgen Receptor
22%
Abiraterone
19%
Neoplasm
14%
Docetaxel
14%
Prostate Specific Antigen
14%
Overall Survival
13%
Diseases
11%
Progression Free Survival
10%
Biological Marker
8%
Immunotherapy
8%
Metastasis
7%
Survival
6%
Chemotherapy
6%
Drug
5%
Prostate Specific Membrane Antigen
5%
Malignant Neoplasm
5%
Taxane
5%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
5%
Biochemistry, Genetics and Molecular Biology
Androgen Receptor
34%
Enzalutamide
21%
Mutation
18%
Germline
11%
Progression Free Survival
10%
Overall Survival
9%
Prostate-Specific Antigen
9%
BRCA2
8%
DNA Repair
7%
Association
6%
Nested Gene
6%
Development
6%
Gene Mutation
5%
Survival
5%
Testosterone
5%